News

Roche launches the cobas® mobile solution, an innovative digital tool designed to boost laboratory efficiency and convenience

  • The cobas mobile solution is Roche’s latest digital tool that allows laboratory professionals to interact with their analysers from anywhere in the lab 
  • The new solution integrates multiple Roche applications helping optimise productivity in lab operations
  • By providing tools to improve and streamline processes, Roche is advancing technology to improve patient care

 

Rotkreuz, 25 November 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the cobas® mobile solution, an innovative tablet application with no location restrictions, making it possible for laboratory personnel to stay connected at all times. Enabling faster decision-making and enhancing walk away time, the cobas mobile solution allows laboratory personnel to interact directly with their analysers* from anywhere in the lab, thereby improving efficiency and convenience. Push notifications indicate if and when intervention is required using an intuitive colour-coding system. The cobas mobile solution integrates seamlessly with multiple Roche applications, including cobas® mobicheck 2.0, cobas® screen share, User Assistance and Roche DiaLog.

“One of the major challenges in laboratory operations is the implementation of efficient workflows and overseeing multiple laboratory analysers, especially in larger laboratories,” said Ann Costello, Head of Centralised and Point of Care Solutions at Roche Diagnostics. “The cobas mobile solution provides laboratories with an intuitive and easy-to-use tool, so they can access and interact with multiple analysers from any location within the lab environment. By providing tools to improve and streamline processes, Roche is advancing technology to improve patient care.”

The cobas mobile solution includes four applications at launch:

  • cobas mobicheck allows laboratory personnel to monitor the alarm, reagent and analyser status of connected cobas® 8000 modular analysers and cobas® pro integrated solutions. Using cobas mobicheck, up to eight analysers can be monitored at one glance from any location within the facility network.
  • cobas screen share enables laboratory personnel to mirror multiple analyser screens on their mobile tablet to interact with them remotely within the lab network.
  • User Assistance is a digital user guide that provides interactive multimedia content with step-by-step instructions.
  • Roche DiaLog simplifies everyday tasks through the single sign-in for instant mobile access to personalised information and insights to effectively manage the daily workload. Roche DiaLog includes additional digital services such as eLabDoc, and eLibrary.

The cobas mobile solution will be further enhanced and extended with additional applications in the future, ensuring it continues to meet the demands of laboratory professionals today and tomorrow.

For media inquiries, please contact

Roche Diagnostics - Centralised and Point of Care Solutions
Phone: +41 (41) 79-24836
Mobile : +41 (79) 41-50778
Email: cps.communications@roche.com
 

cobas® mobile solution

cobas mobile solution

The cobas mobile solution is Roche’s latest digital tool that allows laboratory professionals to interact with their analysers from anywhere in the lab

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.